Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER-RRMM: IberDd vs DVd in Relapsed or Refractory Multiple Myeloma
NCT04975997Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jun 2022
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of iberdomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jun 2022; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04975997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975997.